Ethyl 5-amino-3-isopropylthiophene-2-carboxylate | 936361-40-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: Ethyl 5-amino-3-isopropylthiophene-2-carboxylate
• 英文别名: ethyl 5-amino-3-propan-2-ylthiophene-2-carboxylate
• CAS: 936361-40-9
• 化学式: C₁₀H₁₅NO₂S
• 分子量: 213.301
• InChiKey: MMIPCYHQTTYJNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Imidazo[1,2-a]pyrazine, 6-methyl-8-(methylsulfonyl)-3-[1-[[2-(trimethylsilyl)ethoxy]methyl]-1H-pyrazol-4-yl]- 、 Ethyl 5-amino-3-isopropylthiophene-2-carboxylate 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors

  摘要：

  Our continued effort toward the development of the imidazo[1,2-a] pyrazine scaffold as Aurora kinase inhibitors is described. Bioisosteric approach was applied to optimize the 8-position of the core. Several new potent Aurora A/B dual inhibitors, such as 25k and 25l, were identified. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.008
• 作为产物：
  描述：

  Ethyl 3-(cyanomethylidene)-4-methylpentanoate 在 sulfur 、 二乙胺 作用下， 以 乙醇 为溶剂， 生成 Ethyl 5-amino-3-isopropylthiophene-2-carboxylate
  参考文献：
  名称：

  Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors

  摘要：

  Our continued effort toward the development of the imidazo[1,2-a] pyrazine scaffold as Aurora kinase inhibitors is described. Bioisosteric approach was applied to optimize the 8-position of the core. Several new potent Aurora A/B dual inhibitors, such as 25k and 25l, were identified. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.008

文献信息

• Imidazopyrazines as protein kinase inhibitors
  申请人：Zhao Lianyun

  公开号：US20070117804A1

  公开（公告）日：2007-05-24

  In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.

  本发明的多种实施例提供了一类新型的咪唑吡嗪化合物，作为蛋白质和/或检查点激酶的抑制剂，包括制备这类化合物的方法、包含一个或多个这类化合物的药物组合物、制备包含一个或多个这类化合物的药物制剂的方法，以及使用这类化合物或药物组合物治疗、预防、抑制或改善与蛋白质或检查点激酶相关的一个或多个疾病的方法。
• Methods for inhibiting protein kinases
  申请人：Guzi J. Timothy

  公开号：US20070105864A1

  公开（公告）日：2007-05-10

  The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.

  本发明提供了利用咪唑并[1,2-a]吡嗪化合物抑制来自AKT、检查点激酶、枢纽激酶、Pim-1激酶和酪氨酸激酶的蛋白激酶的方法，以及利用这些化合物治疗、预防、抑制或改善与蛋白激酶相关的一种或多种疾病的方法。
• [EN] IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS<br/>[FR] IMIDAZOPYRAZINES INHIBANT LA PROTEINE KINASE
  申请人：SCHERING CORP

  公开号：WO2007058942A2

  公开（公告）日：2007-05-24

  [EN] In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.
  [FR] La présente invention concerne une nouvelle classe de composés d'imidazopyrazine inhibant une protéine et/ou un checkpoint kinases, des procédés de préparations de tels composés, des compositions pharmaceutiques renfermant un ou plusieurs de ces composés, des procédés de préparation de formulations pharmaceutiques renfermant un ou plusieurs de ces composés et des méthodes de traitement, de prévention, d'inhibition ou d'amélioration d'une ou de plusieurs des maladies associées à la protéine ou au checkpoint kinases, qui utilisent ces composés ou compositions pharmaceutiques.
• [EN] METHODS FOR INHIBITING PROTEIN KINASES<br/>[FR] MÉTHODES D'INHIBITION DE PROTÉINE KINASES
  申请人：SCHERING CORP

  公开号：WO2007056468A1

  公开（公告）日：2007-05-18

  [EN] The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.
  [FR] La présente invention concerne des méthodes d'inhibition de protéine kinases sélectionnées au sein du groupe constitué par l'AKT, la checkpoint kinase, la kinase Aurora, la kinase Pim-1 et la tyrosine kinase, par l'emploi de composés de type imidazo[1,2-a]pyrazine. La présente invention concerne également des méthodes de traitement, de prévention, d'inhibition ou de soulagement d'une ou de plusieurs maladies associées à des protéine kinases par l'utilisation de tels composés.
• Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors
  作者：Zhaoyang Meng、Bheemashankar A. Kulkarni、Angela D. Kerekes、Amit K. Mandal、Sara J. Esposite、David B. Belanger、Panduranga Adulla Reddy、Andrea D. Basso、Seema Tevar、Kimberly Gray、Jennifer Jones、Elizabeth B. Smith、Ronald J. Doll、M. Arshad Siddiqui

  DOI：10.1016/j.bmcl.2010.10.008

  日期：2011.1

  Our continued effort toward the development of the imidazo[1,2-a] pyrazine scaffold as Aurora kinase inhibitors is described. Bioisosteric approach was applied to optimize the 8-position of the core. Several new potent Aurora A/B dual inhibitors, such as 25k and 25l, were identified. (C) 2010 Elsevier Ltd. All rights reserved.